![Lynne M. Brookes](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Lynne M. Brookes
Profile
Ms. Lynne M.
Brookes is Chief Business Officer & Senior Vice President at Galleon Pharmaceuticals, Inc.
Ms. Brookes was previously employed as Vice President-Business Development by Cephalon, Inc., a Sales Associate by Merck & Co., Inc., and a Senior Associate-Endocrine Products by Genentech, Inc.
She received her undergraduate degree from Yale University and an MBA from The Wharton School of the University of Pennsylvania.
Former positions of Lynne M. Brookes
Companies | Position | End |
---|---|---|
MERCK & CO., INC. | Sales & Marketing | - |
Cephalon, Inc.
![]() Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Corporate Officer/Principal | - |
Genentech, Inc.
![]() Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | - |
Galleon Pharmaceuticals, Inc.
![]() Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | Corporate Officer/Principal | - |
Training of Lynne M. Brookes
Yale University | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Experiences
Positions held
Linked companies
Listed companies | 1 |
---|---|
MERCK & CO., INC. | Health Technology |
Private companies | 3 |
---|---|
Galleon Pharmaceuticals, Inc.
![]() Galleon Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Galleon Pharmaceuticals, Inc. develops and manufactures medicines for breathing-control conditions. Its product pipeline addresses the needs of both acute and chronic care patients. The firm's GAL-021 product is a small molecule for intravenous administration designed to support respiratory drive in surgical and critical care patients, and in particular those high risk patients with sleep apnea who are undergoing surgery. The company was founded by James C. Mannion in 2003 and is headquartered in Horsham, PA. | Health Technology |
Cephalon, Inc.
![]() Cephalon, Inc. Pharmaceuticals: MajorHealth Technology Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA. | Health Technology |
Genentech, Inc.
![]() Genentech, Inc. BiotechnologyHealth Technology Genentech, Inc. develops, manufactures and markets pharmaceutical products for life-threatening medical conditions. It studies various areas including oncology, immunology, neuroscience, ophthalmic diseases, microbial pathogenesis, metabolic diseases, cardiovascular diseases, and opportunistic areas. The company was founded by Herb W. Boyer and Robert A. Swanson in 1976 and is headquartered in South San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Lynne M. Brookes